A new report based on national prescription data shows weight-loss drug use is rising among kids and teens. GLP-1 medications, like Ozempic and Wegovy, are drugs originally developed to treat ...

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products In addition to persistence and adherence insights, the Year-3 study found 38% of individuals switched GLP ...

Overpaying for GLP-1 medications is extremely common, with a new data analysis of 102,166 drugs showing that 92% of those prescriptions could have been filled at a lower price. The DoseSpot analysis ...

Now used for type 2 diabetes, new study shows GLP-1 drugs helped people with type 1 keep blood glucose levels in a healthy range while also losing weight.

Changes in eating habits are impacting some categories, like snacks, more than others. Taking GLP-1 drugs reduces a person's ...

Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide, at the end of two years ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Eli Lilly announced successful results from its phase 3 trial of Orforglipron, the first-ever GLP-1, once-daily oral pill for weight loss and type 2 diabetes management.

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who take the same medications. One possible reason for the weight loss ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.